chikungunya vaccine (Ixchiq)

From Aaushi
Jump to navigation Jump to search
[1]

Indications

  • prevention of chikungunya in persons at risk 18-60 years of age

Notes

  • European Medicines Agency temporarily suspended use of Ixchiq elderly > 65 years pending an investigation
  • FDA notes postmarketing reports of 17 serious adverse events, including two deaths, in vaccinated adults between the ages of 62-89 years of age

More general terms

References

  1. ↑ Alvarado D FDA follows EMA in limiting use of Valneva shot BioPharma Dive. May 12, 2025 https://www.biopharmadive.com/news/valneva-chikungunya-vaccine-Ixchiq-pause-fda-cdc-ema/747745/
Retrieved from "https://aaushi.info/w/index.php?title=A59199&oldid=1248668"